GlassScriptPhysician profile
Ling Y Bei
NPI 1164740460
$6,152.90
in general payments reported to CMS, 2019-2025
22 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.24 · 2020: $419 · 2021: $158 · 2022: $987 · 2023: $1,149 · 2024: $1,547 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,468.29 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Alcon Vision LLC | $1,169.98 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Mallinckrodt Hospital Products INC. | $466.93 | 2022-2025 | Acthar |
| Allergan, INC. | $369.13 | 2019-2021 | |
| Harrow Eye, LLC | $340.17 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $294.50 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $246.98 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $231.62 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $225.92 | 2022-2025 | Tyrvaya |
| Nova Eye, INC. | $182.78 | 2024-2025 | |
| Sight Sciences, INC. | $178.51 | 2021-2024 | Omni Surgical System, Tearcare System |
| Horizon Therapeutics Plc | $174.06 | 2020-2023 | Tepezza |
| Thea Pharma INC. | $172.32 | 2023-2025 | Iyuzeh |
| Rxsight INC | $124.03 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $103.81 | 2022-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $100.54 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $91.52 | 2022-2023 | |
| New World Medical,INC. | $63.87 | 2019-2020 | |
| Biotissue Holdings INC. | $51.81 | 2022-2024 | |
| Amgen INC. | $51.67 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $28.42 | 2022-2023 | Flarex |
| Oasis Medical, INC. | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Bei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.